Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
Andrew Blauvelt, Marjolein de Bruin-Weller, Eric L Simpson, Zhen Chen, Marius Ardeleanu, Ana B Rossi, Andrew Blauvelt, Marjolein de Bruin-Weller, Eric L Simpson, Zhen Chen, Marius Ardeleanu, Ana B Rossi
Abstract
Video (MP4 113130 kb).
Trial registration: ClinicalTrials.gov NCT02260986.
Keywords: Atopic dermatitis; Dupilumab; Efficacy; Long-term; Outcome measures.
© 2022. The Author(s).
Figures
Percentage of patients with maintained response at 10 time points (week 16, 20, 24, 28, 32, 36, 40, 44, 48, 52) with dupilumab 300 mg every 2 weeks (q2w) plus topical corticosteroids (TCS) vs placebo plus TCS. Placebo plus TCS: n = 315; dupilumab 300 mg q2w plus TCS: n = 106. For the analysis of Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Peak Pruritus Numerical Rating Scale (NRS), only patients who had baseline values of POEM ≥ 4, DLQI ≥ 4, and NRS ≥ 3 were included. 300 mg q2w, dupilumab 300 mg q2w plus TCS; EASI, Eczema Area and Severity Index; EASI-50/-75/-90, at least a 50, 75 or 90% improvement in EASI
References
- Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi: 10.1038/s41572-018-0001-z.
- Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi: 10.1080/1744666X.2017.1298443.
- Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188–1204. doi: 10.1111/all.14151.
- de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) Br J Dermatol. 2018;178(5):1083–1101. doi: 10.1111/bjd.16156.
- Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1.
- Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020.
- Silverberg JI, Lei D, Yousaf M, et al. What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study. Br J Dermatol. 2021;184(5):888–895. doi: 10.1111/bjd.19457.
- Chalmers JR, Simpson E, Apfelbacher CJ, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Br J Dermatol. 2016;175(1):69–79. doi: 10.1111/bjd.14773.
Source: PubMed